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One implication of the report by Kupas 
et al. (2011) is the possibility that inhibit-
ing RANK-mediated signaling may be a 
rational therapeutic strategy for improving 
the treatment of patients with or at high 
risk of developing metastatic melanoma. 
To date, trials in cancer patients of inhibi-
tion of RANK signaling by RANK ligand 
sequestration have suggested clinical ben-
efit in the management of bone metastasis, 
consistent with the known role of RANK 
in mediating bone remodel ing (Stopeck 
et al., 2010). However, direct antitumor 
effects of this therapy have yet to be dem-
onstrated. The work of Kupas and col-
leagues raises the question of whether 
RANK signaling mediates melanoma cell 
metastasis and provides a basis for devel-
oping preclin ical models to test this.
One important determinant of the effec-
tiveness of anti-RANK therapies will relate 
to whether RANK+ and RANK- melanoma 
cells are hierarchically related in a manner 
consistent with a cancer stem cell model. If 
RANK+ melanoma cells were able to pro-
duce both more RANK+ cells and RANK- 
melanoma cells, but RANK- cells did not 
produce RANK+ cells, then therapeutically 
eliminating or inhibiting the RANK+ cell 
fraction in patients would be expected 
to confer clinical benefit. However, if 
melanoma cells can gain and lose RANK 
expression in a plastic manner, as has been 
described for numerous melanoma cell 
markers (Quintana et al., 2010; Roesch 
et al., 2010), then all melanoma cells will 
need to be eliminated in effective treatment 
strategies, regardless of RANK expression.
The treatment of advanced melanoma 
is currently undergoing revolutionary 
change with the demonstration that anti-
CTLA-4 antibodies prolong life expectancy 
in a significant proportion of patients (Hodi 
et al., 2010). Even greater expectations 
of clinical benefit are held for inhibitors 
of mutated BRAF, which in early-phase 
studies have produced remarkably high 
anti tumor response rates (Flaherty et al., 
2010). However, it is sobering to reflect 
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The molecular mechanisms involved in organ regeneration has biomedical 
implications in regenerative medicine. In this issue, Waters et al. demonstrate 
that levels of the established negative wound healing factor Flightless I (Flii) 
modulate the hair follicle’s capacity to regenerate a fiber-forming bulb after 
amputation. Still to be investigated are the specific pathways through which Flii 
influences regeneration as compared with wound healing.
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An organism’s regenerative capacity 
varies by species and developmental 
stage. Although mammalian tissues 
have limited regenerative capacity 
when compared with the epimorphic 
regeneration seen in urodeles (Endo 
that the majority of patients treated 
with anti-CTLA-4 therapy received no 
overt benefit and that the median dura-
tion of response to BRAF inhibition in 
published studies has been less than 12 
months. Although further development 
of these therapies is a high priority, it will 
be important to define additional thera-
peutic targets in melanoma cells in order 
to expand our armamentarium against 
this disease and provide multipronged 
treatment approaches. It is premature to 
conclude that the RANK signaling path-
way is one of these targets, but the work 
of Kupas et al. (2011) provides a strong 
rationale for further studies to determine 
the biological significance of RANK 
expression on human melanoma cells.
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et al., 2004), in organs such as skin 
and its derived ectodermal appendage 
hair, regeneration can occur as part of 
a homeostatic process and in response 
to wounding. During mammalian 
embryonic development, hair forma-
tion progresses through the hair germ, 
hair peg, and hair bulbous peg to cul-
minate in a fully formed hair shaft–
containing follicle (Mikkola, 2007). 
After its initial morphogenesis, the 
hair follicle undergoes cyclic trans-
formations known as anagen (growth 
phase), catagen (regression phase), 
and telogen (resting phase) through-
out the life of the organism. In addi-
tion to their lifelong recycling capac-
ity, another characteristic of hair fol-
licles is their ability to regenerate after 
partial amputation all components 
necessary for normal hair production 
(Jahoda et al., 1992, 1996). With the 
goal of understanding mechanisms of 
regenerating damaged tissue, Waters 
et al. (2011, this issue) studied the role 
of Flightless I (Flii) using the model 
of rodent vibrissae regeneration after 
surgical amputation of the lower fol-
licular bulb.
Flii, a cytoskeletal remodeling pro-
tein essential for early development 
(Campbell et al., 2002), is character-
ized by a leucine-rich repeat protein–
protein interacting domain in its amino 
terminus and six gelsolin-like seg-
mental repeats in the C-terminal tail 
(Kopechi and Cowin, 2008). Flii was 
previously identified as a negative reg-
ulator of wound healing (Kopechi and 
Cowin, 2008) and subsequently found 
to affect hemidesmosome assembly 
(Kopechi et al., 2009).
Waters et al. (2011) demonstrate 
that Flii is expressed in most compart-
ments of the rodent anagen vibrissae: 
outer root sheath, inner root sheath, 
dermal sheath, and some cells in the 
dermal papilla, but not in the compan-
ion layer. Flii expression varies between 
compartments in regenerating follicles, 
whereas in fully regenerated follicles 
its expression mimics that observed 
in unwounded follicles. Assessment 
of the in vivo regenerative capacity of 
amputated vibrissae using transgenic 
lines expressing low (Flii+/-), normal 
(Flii+/+), and high (FliiTg/Tg) levels of Flii 
exhibited impaired regenerative poten-
tial in Flii+/- follicles. Although the hair 
cycle was not affected in the low or 
high Flii level transgenic lines, overex-
pression of Flii produced significantly 
longer hair fibers. These results indi-
cate that, in contrast to the established 
negative effect on wound healing, Flii 
has a positive role in hair follicle regen-
eration. Characterization of key fac-
tors that might affect the Flii+/- follicles’ 
deficient regeneration indicated that 
a-smooth muscle actin, syndecan-1 
(CD138), P-cadherin, and FGFR2 were 
expressed in temporal and spatial pat-
terns comparable to those observed in 
normal hair follicle development.
Cell division and migration are 
required for successful regeneration 
(Endo et al., 2004), which also requires 
a balance between adhesion and 
motility. It has been established that 
Flii overexpression impedes keratino-
cyte migration and delays wound 
closure, inhibiting hemi desmosome 
assembly, in contrast to Flii+/– mice, 
which exhibit increased wound heal-
ing capacity. In comparing wound 
healing with re generation after ampu-
tation in vibrissae, it seems coun-
terintuitive, as Waters et al. (2011) 
demonstrate, that there is impaired 
hair follicle regeneration with Flii 
deficiency (Flii+/-). The somewhat 
altered Flii expression pattern during 
the regenerative process is possibly 
correlated with a still-undefined 
functional role of Flii in cell adhesion, 
proliferation, migration, and/or con-
traction during regeneration. In the 
context of Flii deficiency, there is 
premature expression of proliferating 
cell nuclear antigen in the migrating 
epithelial outgrowth of the amputated 
hair follicle. The regenerative response 
involves systematic cell proliferation, 
followed by differentiation and pat-
terning. The elevated proliferation in 
Flii+/- regenerative follicles could alter 
the sequence of events necessary for 
successful regeneration.
Thus, although the molecular mech-
anisms by which Flii modulates the 
hair follicle’s ability to regenerate a 
fiber-forming bulb after microsurgical 
removal remain unknown, Flii levels 
seem to be at the nexus of the coordi-
nating pathways.
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Hair follicle 
regeneration 
provides a window 
for opportunities 
to regenerate more 
complex organs in 
mammals.
